Top 5 Psychedelics Milestones In 2021 & What To Expect in 2022 | Science, Funding, Stocks & More

The psychedelic medicines industry had a revolutionary year in 2021. At the start of the year, there were only a couple of publicly traded companies, but by the end of it, there were dozens. These companies are racing to answer questions such as: Can psychedelics cure depression? Can psychedelic treat anxiety? And, can psychedelics help with mental health? Though the answers to these questions have not been proven 100%, after 2021, it does appear more likely than not that the answer to some of these at least, is yes. In this video, we will recap some of the most significant milestones of the psychedelics industry in 2021, and end it with what I am looking forward to in the new year. The first big story of 2021 was the IPOs. Though MindMed (MNMD/MMED) and Compass Pathways (CMPS) went public in 2020, companies such as Field Trip Health (FTRP), Numinus Wellness (NUMI), atai Life Sciences (atai), Cybin Corp (CYBN), and dozens of others joined them in 2021. Add to this the launch of ETFs such as the